- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05230537
En maskeret, placebokontrolleret undersøgelse for at vurdere Iptacopan i aldersrelateret makuladegeneration
En randomiseret, deltager- og efterforskermaskeret, placebo-kontrolleret, multicenter, proof-of-concept-undersøgelse for at vurdere sikkerheden og effektiviteten af LNP023 (Iptacopan) hos patienter med tidlig og mellem aldersrelateret makuladegeneration
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of Iptacopan (LNP023) in participants with early to intermediate age-related macular degeneration in one eye and neovascular age-related macular degeneration in the other eye. All enrolled participants must have early/intermediate AMD in one eye, with at least one high risk optical coherence tomography (OCT) feature (study eye) and neovascular AMD in the other eye (fellow eye).
Participants who meet all of the eligibility criteria will be randomized at the Baseline/Day 1 visit in a 1:1 ratio into one of two treatment arms:
- Iptacopan (LNP023) oral capsules
- Placebo oral capsules Approximately 146 participants (73 per arm) will be treated worldwide.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
London, Det Forenede Kongerige, SE5 9RS
- Novartis Investigative Site
-
Southampton, Det Forenede Kongerige, SO16 6YD
- Novartis Investigative Site
-
-
-
-
California
-
Fullerton, California, Forenede Stater, 92835
- Retina Consultants of Orange County
-
Huntington Beach, California, Forenede Stater, 92647
- Salehi Retina Institute
-
Rancho Cordova, California, Forenede Stater, 95670
- Martel Eye Medical Group
-
Sacramento, California, Forenede Stater, 95841
- Retinal Consultants Medical Group Inc
-
Santa Barbara, California, Forenede Stater, 93103
- California Retina Consultants
-
-
Colorado
-
Durango, Colorado, Forenede Stater, 81303
- Southwest Retina Research Center
-
-
Florida
-
Deerfield Beach, Florida, Forenede Stater, 33064
- Advanced Research LLC
-
Delray Beach, Florida, Forenede Stater, 33484
- Retina Center Of South Florida
-
St. Petersburg, Florida, Forenede Stater, 33711
- Retina Vitreous Associates of Florida
-
-
Indiana
-
Carmel, Indiana, Forenede Stater, 46032
- Midwest Eye Institute
-
-
Louisiana
-
Metairie, Louisiana, Forenede Stater, 70001
- Retina Associates New Orleans
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21209
- Retina Care Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Opthamalic Consultants of Boston
-
-
New Jersey
-
Bloomfield, New Jersey, Forenede Stater, 07003
- Envision Ocular LLC
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Duke Eye Center
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97210
- Retina Northwest PC
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- Charles Retina Institute
-
-
Texas
-
Austin, Texas, Forenede Stater, 78793
- Austin Research Center for Retina
-
Bellaire, Texas, Forenede Stater, 77401
- Retina Consultants TX Rsrch Ctr
-
Dallas, Texas, Forenede Stater, 75231
- Retina Foundation
-
Fort Worth, Texas, Forenede Stater, 76104
- Texas Retina Associates
-
Houston, Texas, Forenede Stater, 77030
- Retina Consultants of Houston PA
-
-
-
-
-
Shanghai, Kina, 200080
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150001
- Novartis Investigative Site
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300020
- Novartis Investigative Site
-
-
-
-
-
Arecibo, Puerto Rico, 00612
- Emanuelli Research and Development Center LLC
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female participants ≥ 50 years of age
- Diagnosis of early or intermediate age-related macular degeneration (AMD) in the study eye as determined by the investigator on fundus examination
- Study eye (early/intermediate AMD eye) must have at least one high risk optical coherence tomography (OCT) feature (as defined by a central reading center).
- Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by the investigator.
- Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required prior to the start of the treatment with LNP023.
- If not received previously, vaccination against Haemophilius influenzae infection should be given, if available and according to local regulations.
Exclusion Criteria:
- History or current diagnosis of ECG abnormalities indicating significant safety risk, such as clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree atrioventricular block (AV block) without a pacemaker.
- History of familial long QT syndrome or known family history of Torsades de Pointes
- History of stroke or myocardial infarction during the 6-month period prior to Baseline/Day 1, any current clinically significant arrhythmias, or any advanced cardiac or severe pulmonary hypertension
- History of end stage kidney disease requiring dialysis or renal transplant
- History of malignancy of any organ system
- History of solid organ or bone marrow transplantation
- History of recurrent meningitis or history of meningococcal infections despite vaccination
- History of immunodeficiency diseases, including a positive Human Immunodeficiency Virus test result at Screening
- Active Hepatitis B (HBV) or Hepatitis C (HCV) infection
- History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.
- Evidence of cRORA or exMNV in the study eye based on multimodal imaging as determined by the central reading center.
- Participants who have current active TB as evidenced by clinical, radiographic and laboratory tests.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Iptacopan (LNP023)
Iptacopan (LNP023) oral use capsules |
oral capsules |
|
Placebo komparator: Placebo
Placebo matched to study drug, oral use capsules |
oral capsules |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imaging
Tidsramme: Baseline/Day 1 through Month 24
|
OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines |
Baseline/Day 1 through Month 24
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The incidence of ocular and non-ocular adverse events (AEs)
Tidsramme: Baseline/Day 1 through Month 24
|
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. |
Baseline/Day 1 through Month 24
|
|
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
Best corrected visual acuity (BCVA) will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
ETDRS low luminance visual acuity (LLVA) scores will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
Pelli-Robson contrast sensitivity measurements will be performed using a Pelli-Robson contrast sensitivity wall chart and recording the number of correct letters read. |
Baseline/Day 1 through Month 24
|
|
Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
|
Pharmacokinetics - concentrations of LNP023 related to trough samples
Tidsramme: Baseline/Day 1 through Month 24
|
Bioanalytical determination of plasma LNP023 concentrations related to trough samples using a LC-MS (mass spectrometry) method. |
Baseline/Day 1 through Month 24
|
|
Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD eye
Tidsramme: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CLNP023E12201
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .